SCHEMBL5447141

SCHEMBL5447141

Cn1c(=O)[nH]c(=O)c2nc(-c3ccccc3)c(Br)nc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.45
PDE1A P54750 1/20 0.45
PDE1B Q01064 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE1C Q14123 1/20 0.45
PDE3A Q14432 1/20 0.45
ALDH1A1 P00352 4/20 0.44
GAA P10253 3/20 0.44
KDM4E B2RXH2 3/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
RECQL P46063 1/20 0.44
MDM2 Q00987 1/20 0.44
MAPK1 P28482 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320759 0.92 KDM4E (0.48) ALDH1A1GAAKDM4EGLAHPGD
SCHEMBL5438411 0.85 PDE3B (0.51) PDE1APDE1BPDE3BPDE1CPDE3A
SCHEMBL5434692 0.84 KDM4E (0.56) PDE5APDE1APDE1BPDE3BPDE1C
SCHEMBL5442836 0.84 TP53 (0.44) ALDH1A1GAAKDM4EGLAHPGD
SCHEMBL5444589 0.79 KMT2A (0.43) ALDH1A1KDM4EHPGDMAPK1MAPT
SCHEMBL1411115 0.75 KDM4E (0.57) PDE3BPDE3AALDH1A1GAAKDM4E
SCHEMBL6192079 0.74 NOS1 (0.52) ALDH1A1GAAKDM4EMAPK1LMNA
SCHEMBL5434638 0.73 MEN1 (0.47) ALDH1A1GAAKDM4EGLAHPGD
SCHEMBL5434556 0.72 ALDH1A1 (0.44) ALDH1A1GAAKDM4EGLAHPGD
SCHEMBL5443537 0.72 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP claimed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO claimed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 PDE5A 2516/4885PDE1A 2253/4885PDE1B 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.